Randomized phase II trial of letrozole plus Anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6822-6830

  Ibrahim, Nuhad K ^a   Yariz, Kemal O ^b   Bondarenko, Ihor ^c   Manikhas, Alexei ^f   Semiglazov, Vladimir ^g   Alyasova, Anna ^h   Komisarenko, Volodymyr ^d   Shparyk, Yaroslav ^e   Murray, James Lee ^a   Jones, David ⁱ   Senderovich, Shai ⁱ   Chau, Albert ⁱ   Erlandsson, Fredrik ⁱ   Acton, Gary ⁱ   Pegram, Mark ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Dnipropetrovsk State Medical Academy   (Ukraine)

^d Regional Public Institution: Kryvyi Rih Oncology Center   (Ukraine)

^e Chemotherapy Department   (Ukraine)

^f St Petersburg Oncological City Hospital   (Russian Federation)

^g N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^h PRIVOLZHSKY RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

ⁱ Antisoma Research Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AS 1402; ESTROGEN RECEPTOR; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIIA; HUMAN ANTIHUMAN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; LETROZOLE; MUCIN 1; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOTYPE; ANEMIA; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; GENETIC POLYMORPHISM; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN ALLOTYPES; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; NEOPLASM STAGING; NITRILES; RECEPTORS, ESTROGEN; RECEPTORS, IGG; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 80455144484     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1151     Document Type: Article

References (25)

1. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) 1981;283: 1432-4. (Pubitemid 12229178)
2. Muss HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, et al. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA). Semin Oncol 1985;12:55-61. (Pubitemid 15149399)
3. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, et al. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol 1988;6:825-31.
4. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606. (Pubitemid 32451796)
5. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67.
6. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006;98: 1285-91. (Pubitemid 44530724)
7. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005;18:1295-304. (Pubitemid 41348648)
8. Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor a. Mol Cell 2006;21:295-305. (Pubitemid 43099944)
9. Holmberg LA, Sandmaier BM. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 2004;3:655-63. (Pubitemid 39576752)
10. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001;93:97-106. (Pubitemid 32539508)
11. Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 2009;11:R73.
12. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumours. Hybridoma 1984;3:223-32. (Pubitemid 15184701)
13. Lundy J, Thor A, Maenza R, Schlom J, Forouhar F, Testa M, et al. Monoclonal antibody DF3 correlates with tumour differentiation and hormone receptor status in breast patients. Breast Cancer Res Treat 1985;5:269-76. (Pubitemid 15060454)
14. Braun DP, Crist KA, Shaheen F, Staren ED, Andrews S, Parker J. Aromatase Inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Am J Surg 2005;190:570-1. (Pubitemid 41306077)
15. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007;12:1084-95. (Pubitemid 350007020)
16. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-8. (Pubitemid 47372612)
17. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26: 1789-96.
18. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
19. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7. (Pubitemid 46606207)
20. Janssen R, Kruit A, Grutters JC, Ruven HJ, Gerritsen WB, van den Bosch JM. The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels. Am J Respir Cell Mol Biol 2006;34:496-9.
21. Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, et al. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer 2010;102:827-32.
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
23. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999;94: 4220-32.
24. Al-Yasi AR, Carroll MJ, Ellison D, Granowska M, Mather SJ, Wells CA, et al. Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG-I. Br J Cancer 2002;86:870-8. (Pubitemid 34271021)
25. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A 2009;106:5837-41.